UY29323A1 - Uso de colorantes de cianina para el dignostico de enfermedades proliferativas - Google Patents

Uso de colorantes de cianina para el dignostico de enfermedades proliferativas

Info

Publication number
UY29323A1
UY29323A1 UY29323A UY29323A UY29323A1 UY 29323 A1 UY29323 A1 UY 29323A1 UY 29323 A UY29323 A UY 29323A UY 29323 A UY29323 A UY 29323A UY 29323 A1 UY29323 A1 UY 29323A1
Authority
UY
Uruguay
Prior art keywords
dignostic
proliferative diseases
cyanine
colors
cyanine colors
Prior art date
Application number
UY29323A
Other languages
English (en)
Inventor
Michael Schirner
Kai Licha
Martin Pessel
Malte Bahner
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34933224&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY29323(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of UY29323A1 publication Critical patent/UY29323A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Uso del colorante de cianina SF64 para el diagnóstico de enfermedades proliferativas con una administración que comprende menos que 5 mg/kg de peso corporal
UY29323A 2005-01-07 2006-01-02 Uso de colorantes de cianina para el dignostico de enfermedades proliferativas UY29323A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05000276A EP1679082A1 (en) 2005-01-07 2005-01-07 Use of cyanine dyes for the diagnosis of proliferative diseases

Publications (1)

Publication Number Publication Date
UY29323A1 true UY29323A1 (es) 2006-10-02

Family

ID=34933224

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29323A UY29323A1 (es) 2005-01-07 2006-01-02 Uso de colorantes de cianina para el dignostico de enfermedades proliferativas

Country Status (23)

Country Link
EP (2) EP1679082A1 (es)
JP (1) JP5578765B2 (es)
KR (1) KR20070092270A (es)
CN (1) CN101128218A (es)
AR (1) AR052190A1 (es)
AU (1) AU2006204496A1 (es)
BR (1) BRPI0606411A2 (es)
CA (1) CA2594390C (es)
CR (1) CR9232A (es)
DO (1) DOP2006000005A (es)
GT (1) GT200600001A (es)
IL (1) IL182499A0 (es)
MX (1) MX2007008300A (es)
NO (1) NO20074036L (es)
NZ (1) NZ554917A (es)
PA (1) PA8659101A1 (es)
PE (2) PE20060872A1 (es)
RU (1) RU2007129919A (es)
TW (1) TW200635612A (es)
UA (1) UA89976C2 (es)
UY (1) UY29323A1 (es)
WO (1) WO2006072580A1 (es)
ZA (1) ZA200706533B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE374367T1 (de) * 2004-07-22 2007-10-15 Bayer Schering Pharma Ag Verwendung von cyanin-farbstoffen zur diagnose von krankheiten, welche mit angiogenese assoziert sind
EP1679082A1 (en) * 2005-01-07 2006-07-12 Schering AG Use of cyanine dyes for the diagnosis of proliferative diseases
EP1743658A1 (en) * 2005-07-14 2007-01-17 Schering Aktiengesellschaft Optical imaging of rheumatoid arthritis
WO2008119493A1 (en) * 2007-03-30 2008-10-09 F. Hoffmann-La Roche Ag Composition of labeled and non-labeled monoclonal antibodies
US20110262354A1 (en) 2007-07-13 2011-10-27 Emory University Cyanine-containing compounds for cancer imaging and treatment
GB0803477D0 (en) 2008-02-26 2008-04-02 Ge Healthcare As Therapy selection method
CN102099059B (zh) * 2008-06-13 2015-09-23 西塞医疗中心 用于癌症靶向治疗的小分子配体-药物轭合物
GB0814960D0 (en) * 2008-08-15 2008-09-24 Ge Healthcare As Method for detecting dysplasia
JP2012532846A (ja) 2009-07-09 2012-12-20 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト インビボ腫瘍脈管構造画像処理
CA2768330A1 (en) 2009-07-28 2011-02-03 F. Hoffmann-La Roche Ag Non-invasive in vivo optical imaging method
AU2010286592B2 (en) 2009-08-28 2015-08-13 Visen Medical, Inc. Systems and methods for tomographic imaging in diffuse media using a hybrid inversion technique
JP2011046663A (ja) 2009-08-28 2011-03-10 Fujifilm Corp 近赤外蛍光造影剤
JP2011046662A (ja) 2009-08-28 2011-03-10 Fujifilm Corp 近赤外蛍光造影剤
US8401619B2 (en) 2009-09-22 2013-03-19 Visen Medical, Inc. Systems and methods for virtual index-matching of diffusive media
WO2011138462A1 (en) 2010-05-07 2011-11-10 F. Hoffmann-La Roche Ag Diagnostic method for the detection of cells ex vivo
WO2012119999A1 (en) 2011-03-07 2012-09-13 F. Hoffmann-La Roche Ag Means and methods for in vivo testing of therapeutic antibodies
EP2683413A1 (en) 2011-03-07 2014-01-15 F.Hoffmann-La Roche Ag In vivo selection of therapeutically active antibodies
KR101373108B1 (ko) 2012-01-20 2014-03-27 이화여자대학교 산학협력단 폴리메틴 체인에 메조-반응작용기를 갖는 신규한 시아닌 유도체 및 이의 제조방법
CN102608051B (zh) * 2012-02-21 2015-04-08 中国科学院化学研究所 用于诊断白血病的试剂盒
CN102703569B (zh) * 2012-05-24 2014-04-09 中国科学院化学研究所 菁染料的新用途
CN102706787B (zh) * 2012-05-24 2015-04-08 中国科学院化学研究所 菁染料的新用途
CN104853669B (zh) 2012-10-15 2017-07-21 文森医学公司 具有荧光及生物发光源的交叉形态加权特征的漫射介质成像的系统、方法及设备
US20150182518A1 (en) * 2012-10-26 2015-07-02 Canon Kabushiki Kaisha Cancer cell inhibitory drug and cancer stem-cell detection probe
WO2014092958A1 (en) * 2012-12-10 2014-06-19 Molecular Targeting Technologies, Inc. Compositions and methods of diagnosing ocular diseases
JP6681334B2 (ja) 2013-12-31 2020-04-15 メモリアル スローン ケタリング キャンサー センター リアルタイムの蛍光源のマルチチャネル撮像のためのシステム、方法、および装置
RU2565645C1 (ru) * 2014-09-05 2015-10-20 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ рентгендиагностики глубины инвазии рецидива рака вульвы в мягкие ткани
EP3233134B1 (en) 2014-12-15 2020-03-25 Memorial Sloan-Kettering Cancer Center Cyclic peptides with enhanced nerve-binding selectivity, nanoparticles bound with said cyclic peptides, and use of same for real-time in vivo nerve tissue imaging
CA3007657A1 (en) 2015-12-15 2017-06-22 Memorial Sloan Kettering Cancer Center Imaging systems and methods for tissue differentiation, e.g., for intraoperative visualization
US11660354B2 (en) 2016-11-30 2023-05-30 Memorial Sloan Kettering Cancer Center Inhibitor-functionalized ultrasmall nanoparticles and methods thereof
CN111970960A (zh) 2018-03-30 2020-11-20 珀金埃尔默健康科学有限公司 使用短波红外(swir)投影层析成像对解剖器官和内含物进行3d重建的系统和方法
EP4015004A1 (en) 2020-12-18 2022-06-22 Phi Pharma SA Proteoglycan specific branched peptides

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000095758A (ja) * 1998-09-18 2000-04-04 Schering Ag 近赤外蛍光造影剤および蛍光造影方法
DE19917713A1 (de) * 1999-04-09 2000-10-19 Diagnostikforschung Inst Kurzkettige Peptid-Farbstoffkonjugate als Konstrastmittel für die optische Diagnostik
DE19947559A1 (de) * 1999-09-24 2001-04-19 Schering Ag Antikörper-Farbstoffkonjugate gegen Zielstrukturen der Angiogenese zur intraoperativen Tumorranddarstellung
MXPA05007668A (es) * 2003-01-24 2005-09-30 Schering Ag Colorantes hidrofilicos de cianina, reactivos a tiol y conjugados de los mismos con biomoleculas para diagnostico por fluorescencia.
ATE374367T1 (de) * 2004-07-22 2007-10-15 Bayer Schering Pharma Ag Verwendung von cyanin-farbstoffen zur diagnose von krankheiten, welche mit angiogenese assoziert sind
EP1679082A1 (en) * 2005-01-07 2006-07-12 Schering AG Use of cyanine dyes for the diagnosis of proliferative diseases

Also Published As

Publication number Publication date
NZ554917A (en) 2010-01-29
CR9232A (es) 2007-11-23
JP5578765B2 (ja) 2014-08-27
AU2006204496A1 (en) 2006-07-13
CA2594390A1 (en) 2006-07-13
DOP2006000005A (es) 2006-07-15
PE20100449A1 (es) 2010-07-25
TW200635612A (en) 2006-10-16
KR20070092270A (ko) 2007-09-12
NO20074036L (no) 2007-08-03
CA2594390C (en) 2013-10-22
EP1679082A1 (en) 2006-07-12
EP1833513B1 (en) 2013-03-06
ZA200706533B (en) 2009-07-29
JP2008526802A (ja) 2008-07-24
MX2007008300A (es) 2007-09-07
AR052190A1 (es) 2007-03-07
RU2007129919A (ru) 2009-02-20
EP1833513A1 (en) 2007-09-19
WO2006072580A1 (en) 2006-07-13
BRPI0606411A2 (pt) 2009-06-23
PA8659101A1 (es) 2006-09-08
IL182499A0 (en) 2007-09-20
CN101128218A (zh) 2008-02-20
PE20060872A1 (es) 2006-10-01
UA89976C2 (ru) 2010-03-25
GT200600001A (es) 2006-08-22

Similar Documents

Publication Publication Date Title
UY29323A1 (es) Uso de colorantes de cianina para el dignostico de enfermedades proliferativas
AR062448A1 (es) Conjugados de analogos de aziridinil-epotilona y composiciones farmaceuticas que comprenden los mismos
CL2008001303A1 (es) Compuestos derivados de heterociclos, moduladores de gamma secretasa; composicion farmaceutica; kit farmaceutico; y uso en el tratamiento del alzheimer.
GT201000008A (es) Agentes citotoxicos que comprenden nuevos derivados de tomaimicina y su uso terapeutico
ECSP099822A (es) Derivados de guanina policiclicos y sus métodos de uso
HN2005000795A (es) Pirimidinas como antagonistas del receptor de prostaglandina d2
CL2012000248A1 (es) Compuesto conjugado de insulina; procedimiento de preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; kit farmaceutico; uso en el tratamiento de trastornos mediados por insulina.
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
SV2006002473A (es) Forma cristalina ortorrombica del maleato de asenapina y su uso en el tratamiento de trastornos mentales ref. 2005.893 (806.671)
CL2007002167A1 (es) Compuestos derivados de indol, antagonistas iap; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de cancer.
CL2008002538A1 (es) Compuestos derivados de indol sustituidos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral
AR059390A1 (es) Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopausicos
CL2008001821A1 (es) Compuestos derivados de imidazo[2,1-b]-tiazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes, sindrome metabolico, resistencia a la insulina, entre otras.
AR053803A1 (es) Uso de acido pinolenico
CL2007002891A1 (es) Trans-5-cloro-2-metil-2,3,3a,12b-tetrahidro-1h-dibenz-[2,3:6,7]oxepino[4,5-c]pirrol 50% amorfo en base al peso total del compuesto; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento de un trastorno seleccionado entre e
HN2003000183A (es) Difenilazetidinonas sustituidas en anillo procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.
PA8599401A1 (es) Nueva difenilazetidinona con propiedades fisiologicas mejoradas, procedimiento para su preparacion, medicamentos que comprenden este compuesto y su uso
HN2008000360A (es) Dispersiones amorfas solidas
AR070025A1 (es) Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica
CR10842A (es) Derivados de acetileno y su uso para la union a placas amiloides y su diagnostico por imagenes
AR058173A1 (es) Uso de sdf-1 para el tratamiento y/o prevencion de enfermedades neurologicas
UY30046A1 (es) Nuevos derivados de furopirimidina acíclicos sustitiudos y su uso
HN2010000128A (es) Imidazoles sustituidos con heterociclilamida
GT200600106A (es) Agentes endoparasiticidas
DOP2010000197A (es) Derivados de oxindol sustituidos y uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20160805